Type 1 Diabetes Clinical Trial
Official title:
Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREAMED Trail
Closed loop technology has been shown to reduce both hypoglycemia and hyperglycemia, as well
as reduce glycemic variability.
Several groups around the world investigate efforts in developing closed-loop systems.
Investigators combined two closed-loop systems with different mode of operation in order to
enhance the closed-loop system. The two systems are Hybrid closed-loop system and the
MD-Logic closed-loop system . The combined algorithm Hybrid logic closed loop (HLCL) was
tested 'In silico' and was proved to be safe and effective. The next step is to test the
system in a clinical study in a supervised environment in a camp.
The two systems were tested separately in several clinical studies and were proven to be safe
and effective in a diverse population of patients with type 1 diabetes. The MD-Logic system
for overnight use "the GlucoSitter" has a CE mark.
The purpose of this study is to collect data on the feasibility of the HLCL system in a camp
setting.
Closed loop technology has been shown to reduce both hypoglycemia and hyperglycemia, as well
as reduce glycemic variability.
Several groups around the world investigate efforts in developing closed-loop systems.
Investigators combined two closed-loop systems with different mode of operation in order to
enhance the closed-loop system. The two systems are Hybrid closed-loop system and the
MD-Logic closed-loop system . The combined algorithm Hybrid logic closed loop (HLCL) was
tested 'In silico' and was proved to be safe and effective. The next step is to test the
system in a clinical study in a supervised environment in a camp.
The two systems were tested separately in several clinical studies and were proven to be safe
and effective in a diverse population of patients with type 1 diabetes. The MD-Logic system
for overnight use "the GlucoSitter" has a CE mark.
The primary objective of the study is to characterize the overall management of the glycemic
control using this system including Safety. The data collected in this study will be used to
confirm/develop the HLCL System further.
Secondary objectives of this study include evaluation of the HLCL system in a monitored
setting (camp) with the following stresses:Exercise, high carbohydrate and high fat meals
This study is a single-arm, single-center, in clinic Investigation in subjects with type 1
diabetes on insulin pump therapy.
Run-in Period:
A total of up to 10 subjects will be enrolled (age 18-40). A minimum of 6 days run-in period
with sensor augmented pump will be used to collect sensors and insulin data and to allow the
subject to become familiar.
Study Period - Camp:
Following the run-in period subjects will participate in a 5 day, 4 night study period in a
camp setting during which the HLCL feature will be studied.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
| Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
| Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
| Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
| Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
| Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
| Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
| Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
| Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
| Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
| Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
| Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
| Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
| Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
| Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
| Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |